Induction of Differentiation in Human Hepatocarcinoma Cells by Isoverbascoside

Chen, Ruichuan; Jin-Hua, Su; Gao-Liang, Ouyang; Ke-Xia, Cai; Li, Jinquan; Xie, Xiaochen

doi:10.1055/s-2002-26759

Cited by 15 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among these are Ligstrum purpurascens (Wong et al, 2001ab), Brandisia hancei (He et al 2001), Veronica persica (Harput et al 2002), Pedicularis striata (Chen et al 2002), Cistanche salsa (Pu et al 2003), Buddleja officinalis (Lee et al 2005), Callicarpa dichotoma (Koo et al 20052006;Lee et al 2006b), Clerodendron trichotomum (Lee et al 2006a2007), Cistanche deserticola and Boschniakia rossica (Wu et al 2006), Scrophularia ningpoenis (Huang et al 2008), Rehmannia glutinosa (Li et al 2006), and Harpagophytum procumbens (Boje et al 2003). Acteoside was reported to exhibit antioxidant activities (Wong et al 2001b) from bitter tea ( Ligstrum purpurascens ), a popular beverage in southern China.…”

Section: Introductionmentioning

confidence: 99%

Inhibitory activities of acteoside, isoacteoside, and its structural constituents against protein glycation in vitro

Liu

Han

et al. 2013

Bot Stud

View full text Add to dashboard Cite

BackgroundAdvanced glycation end products (AGE) are substances that can induce insulin resistance in adipocyte, hepatocyte and muscle cells. This resistance correlates highly with cardiovascular disease and diabetic complications. Acteoside (A), a phenylethanoid glycoside, is an active compound in several plants and traditional herbal medicines. Acteoside, its structural isomer, isoacteoside (I), and their constituents, caffeic acid (C) and 3,4-dihydroxyphenylethanol (D), were used in the study to investigate the inhibitory activity against AGE formations in vitro.ResultsAGE formations were detected by anti-(Nϵ-(carboxymethyl)lysine (anti-CML), using bovine serum albumin (BSA)/glucose (glc) and BSA/galactose (gal) as models, or by anti-argpyrimidine (anti-AP), using BSA/methylglyoxal (MGO) as models. It was found that A, I, C, or D, each at 5 mM, could attenuate the CML formations detected by ELISA in the BSA/gal model of a 3-day or 5-day reaction, and showed significant differences (P < 0.01 or P < 0.001) compared to the control. However, these compounds showed a minor effect after a 7-day incubation. It was also found that C or D could lower the CML formations in the BSA/glc model and showed significant differences (P < 0.05 or P < 0.01) compared to the control after a 3-day, 5-day and 7-day reaction. It was found that A, I, C, or D, each at 0.5 mM or 5 mM, could attenuate the AP formations in the BSA/MGO model of a 3-day reaction and showed significant differences (P < 0.001) compared to the control.ConclusionsThe results suggest the potential anti-glycation activities of A and I in vitro may apply to cell models at higher glucose concentrations or to diabetic animal models, and need further investigation.Electronic supplementary materialThe online version of this article (doi:10.1186/1999-3110-54-6) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

Inhibitory activities of acteoside, isoacteoside, and its structural constituents against protein glycation in vitro

Liu

Han

et al. 2013

Bot Stud

View full text Add to dashboard Cite

show abstract

“…The combination of Astragalus membranaceus and Salvia miltiorrhiza extract has been found to increase the differentiation of HCC cells by modulating TGF-β/TβR and Imp7/8 protein expression[ 99 ]. Additionally, Rui-Chuan et al [ 100 ] reported that isoverbascoside induced SMMC-7721 differentiation, thereby acting as a potential anti-tumor target[ 100 ]. The compounds and formulas applied for preventing HCC recurrence via inhibition of cancer stemness are presented in Table 3 .…”

Section: Inhibiting Cancer Stemnessmentioning

confidence: 99%

Roles of conventional and complementary therapies in recurrent hepatocellular carcinoma

Lai¹,

Lin²,

Jeng³

et al. 2023

World J Gastrointest Oncol

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common type of cancer and the fourth leading cause of cancer-related deaths in the world. HCC has a reported recurrence rate of 70%-80% after 5 years of follow-up. Controlling tumor recurrence is the most critical factor associated with HCC mortality. Conventional salvage therapies for recurrent HCC include re-hepatectomy or liver transplantation, transcatheter arterial chemoembolization, Y-90, target therapy, and immunotherapy; however, these conventional treatment modalities have yet to achieve consistently favorable outcomes. Meanwhile, previous studies have demonstrated that conventional therapies in combination with traditional Chinese medicine (TCM), acupuncture, moxibustion or dietary supplements could notably benefit patients with HCC recurrence by strengthening and augmenting the overall management strategy. However, systemic reviews related to the interactions between complementary therapies and conventional therapy in recurrent HCC are limited. In this review, we discuss the molecular mechanisms underlying the functions of complementary therapies for recurrent HCC, which include augmenting the local control to improve the congestion status of primary tumors and reducing multicentric tumor occurrence via inducing autophagy, apoptosis or cell cycle arrest. TCM and its derivatives may play important roles in helping to control HCC recurrence by inhibiting epithelial-mesenchymal transition, migration, invasion, and metastasis, inhibiting cancer stem cells, and ameliorating drug resistance.

show abstract

“…The results of semi-soft agar colony assay, a method which estimate tumorigenicity of cancer cells, revealed that IVer is capable of inducing differentiation in human hepatocarcinoma cells (SMMC-7721). Vervascoside-induced differentiation was associated with several phenomena, including arresting G0/G1 phase, suppressing γ-glutamyltransferase activity (a marker enzyme of hepatocarcinoma cells), and elevating tyrosine aminotransferase activity (an indicator of differentiated hepatic cells) [121]. In addition, in human gastric cancer cell line MGC 803, IVer inhibited cell proliferation, induced differentiation and G0/G1 arrest, as well as suppressed alkaline phosphatase (ALP), and lactate dehydrogenase (LDH) [122].…”

Section: Isoverbascoside (Iver)mentioning

confidence: 99%

Phytochemical Profiling and Pharmacological Activities of Rydingia Michauxii: A Review

Tahmasebi¹,

Jamali²,

Atabaki³

et al. 2023

Preprint

View full text Add to dashboard Cite

Bioactive plant compounds, also known as phytochemicals, are essential for plant resistance, growth, and development. These chemicals often possess therapeutic properties that have been used in traditional medicine for centuries as herbal remedies for a variety of diseases. As a member of the Lamiaceae family, Rydingia (Syn: Otostegia) is found in Asia and northeastern Africa. R. michauxii, is a unique shrub that grows in the Southern region of Iran, Fars province. Rydingia species have been used as traditional herbal medicine in Iran for many years. It seems that R. michauxii offers great potential for in-depth research on its diverse biological properties, especially its antioxidant and lipid-lowering effects. Nevertheless, no clinical investigation has been carried out on the phytochemical characteristics of this plant to date. Therefore, this study aims to contribute to the scientific knowledge on the pharmacological properties of R. michauxii and its phytochemical compounds and encourage researchers to evaluate its biological properties in animal models. In this study, all available scientific literature was compiled and all phytochemical and pharmacological properties of the R. michauxii plant were investigated, including antibacterial, antifungal, antiviral, antioxidant, antimalarial, cytotoxic, and lipid-lowering effects, which may prove useful in developing novel formulations with greater therapeutic benefits in clinical applications.

show abstract

Induction of Differentiation in Human Hepatocarcinoma Cells by Isoverbascoside

Cited by 15 publications

References 8 publications

Inhibitory activities of acteoside, isoacteoside, and its structural constituents against protein glycation in vitro

Inhibitory activities of acteoside, isoacteoside, and its structural constituents against protein glycation in vitro

Roles of conventional and complementary therapies in recurrent hepatocellular carcinoma

Phytochemical Profiling and Pharmacological Activities of Rydingia Michauxii: A Review

Contact Info

Product

Resources

About